Stemline Therapeutics is a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. ELZONRIS® (tagraxofusp-erzs) was approved by the United States Food and Drug Administration, and is commercially available in the United States for the treatment of adult and pediatric patients, two years and older, with blastic plasmacytoid dendritic cell neoplasm. In addition, Co. is also assessing ELZONRIS, as both single agent and in combination, in a variety of other indications including Phase 1 and 2 clinical trials in chronic myelomonocytic leukemia, myelofibrosis, multiple myeloma, and acute myeloid leukemia. We show 33 historical shares outstanding datapoints in our STML shares outstanding history coverage, used to compute STML market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing STML market cap history over the course of time is important for investors
interested in comparing STML's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of STML versus a peer is one thing; comparing
STML market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like STML can fluctuate over the course of history.
With this page we aim to empower investors researching STML by allowing them to research the STML market cap history. |
Free STML Email Alerts:
Video: The Importance of Market Cap
